

Search

EN

Back

Biogen Secures EU Approval for High-Dose SPINRAZA, Bolstering SMA Franchise

Back

Stock NewsThemesBiogen Secures EU Approval for High-Dose SPINRAZA, Bolstering SMA Franchise

Cancer Research

Biogen Secures EU Approval for High-Dose SPINRAZA, Bolstering SMA Franchise

Edgen Stock·Jan 12 2026, 23:46

Share to

Share to

Copy link

source:

[1] Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Recommend

Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder ReturnsNov 28 2025, 10:17 US-China AI Rivalry Enters New Phase Focused on Compute Power and CybersecurityNov 28 2025, 10:17 Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder ReturnsNov 28 2025, 10:17

Hot News

Virtual Reality (VR)Xiaomi EV Unit Hits 25.5% Margin, Powering Profit ShiftJan 12 2026, 20:35

US Seizes Russian Tanker, Escalating Direct Pressure on PutinJan 12 2026, 09:02

Nancy PelosiUS-China AI Rivalry Enters New Phase Focused on Compute Power and CybersecurityJan 12 2026, 08:56

Societe Generale Forecasts Fed Rate Cuts Driving Treasury Yields Lower Through 2026Dec 01 2025, 07:07